Sanofi (SNY) Cash from Financing Activities (2019 - 2026)

Sanofi has reported Cash from Financing Activities for 6 years, with the latest figure at -$2.1 billion in Q2 2026.

• Quarterly Cash from Financing Activities rose 52.44% year-over-year to -$2.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$20.0 billion (down 68.1% YoY) and the FY2025 annual result came in at -$9.6 billion, down 55.13% from the prior year.
• Cash from Financing Activities fell to -$2.1 billion in Q2 2026 per SNY's latest filing, from -$1.8 billion in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $825.6 million in Q1 2024 and troughed at -$9.6 billion in Q4 2025.
• A 3-year average of -$3.5 billion and a median of -$2.1 billion in 2026 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities plunged 510.48% in 2025, then surged 52.44% in 2026.
• Over 3 years, Cash from Financing Activities stood at -$6.2 billion in 2024, then slumped by 55.13% to -$9.6 billion in 2025, then jumped by 78.04% to -$2.1 billion in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$2.1 billion, -$1.8 billion, and -$9.6 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.